Aveeno

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

Retrieved on: 
Monday, February 26, 2024
TSX, Toronto Stock Exchange, Exercise, Transaction, Aeterna, Avenanthramide, Text, Pharmacy, Proxy, Neutrogena, Aveeno, Research, Management

These revenue streams will be used to support the development of high potential-return products and represent a more diversified value proposition for investors.

Key Points: 
  • These revenue streams will be used to support the development of high potential-return products and represent a more diversified value proposition for investors.
  • The issuance of Aeterna Zentaris Shares, Transaction Warrants and Replacement Options by Aeterna Zentaris under the Transaction is subject to the approval of a simple majority of the votes cast by Aeterna shareholders at a special meeting of Aeterna Zentaris shareholders.
  • ISS recommended that Aeterna Zentaris shareholders vote FOR all of these resolutions as part of the Transaction.
  • Aeterna Zentaris and Ceapro securityholders must vote their proxy before 11:00 a.m. (Eastern time) on March 8, 2024.

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

Retrieved on: 
Monday, February 26, 2024
TSX, Toronto Stock Exchange, Exercise, Transaction, Aeterna, Avenanthramide, Text, Pharmacy, Proxy, Neutrogena, Aveeno, Research, Management

These revenue streams will be used to support the development of high potential-return products and represent a more diversified value proposition for investors.

Key Points: 
  • These revenue streams will be used to support the development of high potential-return products and represent a more diversified value proposition for investors.
  • The issuance of Aeterna Zentaris Shares, Transaction Warrants and Replacement Options by Aeterna Zentaris under the Transaction is subject to the approval of a simple majority of the votes cast by Aeterna shareholders at a special meeting of Aeterna Zentaris shareholders.
  • ISS recommended that Aeterna Zentaris shareholders vote FOR all of these resolutions as part of the Transaction.
  • Aeterna Zentaris and Ceapro securityholders must vote their proxy before 11:00 a.m. (Eastern time) on March 8, 2024.

Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro

Retrieved on: 
Thursday, February 15, 2024
Letter, Shareholder, TSX, Toronto Stock Exchange, Growth, Risk, Proxy, Pharmacy, Knowledge, Neutrogena, Aveeno, FGS

The two innovative biopharmaceutical development companies previously announced that they had entered into a definitive agreement to combine operations in an all-stock merger of equals transaction (the "Transaction").

Key Points: 
  • The two innovative biopharmaceutical development companies previously announced that they had entered into a definitive agreement to combine operations in an all-stock merger of equals transaction (the "Transaction").
  • A new name for the combined company is expected to be announced following the closing of the Transaction.
  • Ceapro currently generates revenues from two main active ingredients, oat beta glucan and avenanthramides, extracted and purified using its proprietary technology.
  • Both companies have expertise that can build upon each other, which is expected to result in a stronger combined company.

Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris

Retrieved on: 
Thursday, February 15, 2024
Court, Issuer, Shareholder, Arrangement, Post office box, Meeting, TSX, Toronto Stock Exchange, News, Aeterna, Avenanthramide, Proxy, Pharmacy, Knowledge, Neutrogena, Aveeno, Internet, Security (finance)

The Board believes this is a compelling opportunity for Ceapro and its investors for a number of reasons, including:

Key Points: 
  • The Board believes this is a compelling opportunity for Ceapro and its investors for a number of reasons, including:
    Recurring revenue to support business expansion.
  • The pipeline of products being developed should generate an increased and consistent news flow, a key supporting factor in investor interest.
  • Only Securityholders of record as of the close of business on January 12, 2024 are eligible to vote at the Meeting.
  • Registered Securityholders and duly appointed proxyholders may vote on matters presented at the Meeting by:
    Virtually – completing a ballot online during the Meeting.

Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company

Retrieved on: 
Thursday, December 14, 2023
Par value, Aveeno, EDGAR, Research, Pharmacy, LLP, Consolidation, Transaction, TMX Group, Neutrogena, FGS, Arrangement, Growth, TSX, Toronto Stock Exchange, Exercise, Blake, Cassels & Graydon, Security (finance)

Shareholders of each company will share in future value creation, with existing securityholders of Aeterna and Ceapro to each own 50% of the combined company, respectively (assuming the exercise of all Transaction Warrants (as defined below)).

Key Points: 
  • Shareholders of each company will share in future value creation, with existing securityholders of Aeterna and Ceapro to each own 50% of the combined company, respectively (assuming the exercise of all Transaction Warrants (as defined below)).
  • The anticipated dual Nasdaq and TSX listing is expected to provide additional volume and an improved capital market profile for the combined company.
  • The terms of the Transaction are set out in a definitive arrangement agreement (the “Arrangement Agreement”) between Aeterna and Ceapro.
  • Similarly, certain officers and directors of Aeterna have entered into lock-up agreements with Ceapro, agreeing to vote their Aeterna common shares in favour of the Transaction.

THE NATIONAL ECZEMA ASSOCIATION (NEA) PRESENTS ITS ANNUAL ECZEMA AWARENESS MONTH IN OCTOBER, HIGHLIGHTING KEY TRUTHS ABOUT THE INFLAMMATORY SKIN DISEASE THAT BURDENS 1 in 10 AMERICANS

Retrieved on: 
Thursday, September 28, 2023
EAM, Dermatitis, Patient, Sleep, Inflammation, Social media, Aveeno, Rash, Eli Lilly, Pain, NEA, AbbVie, LEO, L'Oréal, Knowledge, Skin, Caregiver, Disease, Silk, Pharmaceutical industry, Incyte, Pfizer

NOVATO, Calif. , Sept. 28, 2023 /PRNewswire/ -- The National Eczema Association (NEA) presents its annual Eczema Awareness Month (EAM) in October, highlighting different aspects of living with eczema— the debilitating, inflammatory and non-contagious skin disease that burdens 1 in 10 adults and children in the United States, equaling 31.6 million people.1, 2  

Key Points: 
  • Members of the eczema community will share their personalized "one thing," powerfully illustrating the diversity and complexity of this life-altering skin disease.
  • Each week of the 2023 Eczema Awareness Month will look at #OneThingAbout Eczema as follows:
    Week 2 (October 9-15, 2023)—One thing about eczema: It's more than just a rash.
  • Week 3 (October 16-22, 2023)-–One thing about eczema: It can't be cured but it can be managed and treated.
  • NEA's Eczema Awareness Month 2023 is supported in part by the following sponsors: AbbVie, Sanofi/Regeneron, Eli Lilly, LEO, Pfizer, Incyte, Arcutis, CeraVe, Aveeno and Earth Mama.

North America Cosmetic Bioactive Ingredients Market 2022-2028: Increase in Male-Centric Products Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Cosmetics, Retail, Growth, Antioxidant, Hair, Aloe vera, Aveeno, Fatigue, Forecasting, Ageing, Cosmetics

The "North America Cosmetic Bioactive Ingredients Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Cosmetic Bioactive Ingredients Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • According to the publisher, the cosmetic bioactive ingredients market in North America is estimated to obtain a CAGR of 5.90% over the forecasting years from 2022 to 2028.
  • Therefore, the rise in the production of natural personal care products fuels the cosmetic bioactive ingredients market's growth.
  • Thus, these factors are anticipated to elevate the cosmetic bioactive ingredients market's growth over the forecast period.

AVEENO® RELEASES NEW REPORT REVEALING THAT 71% OF ADULTS HAVE SENSITIVE SKIN

Retrieved on: 
Tuesday, October 25, 2022
Quality of life, Emotion, Psoriasis, Culture, Skin, Prevalence, Excoriation disorder, Dermatology, Contest, Patient, Sleep, Depression, Rosacea, Health, Atopic dermatitis, Awareness, Research, Social media, Environment, Anxiety, Leisure, Acne, Solution, Leadership, Cosmetics, Aveeno

SKILLMAN, N.J., Oct. 25, 2022 /PRNewswire/ -- Today, the Aveeno® brand launched its first-ever State of Skin Sensitivity Report, which examines the causes of sensitive skin, and explores the connection between body, mind, and skin. While body positivity has spread to mainstream culture in recent years, self-love can be challenging for those of us with sensitive skin. The groundbreaking Aveeno® report shows that 71% of adults identify as having sensitive skin1,2, an astounding increase of 55%3,4 in just two decades. The impact of this sensitivity is more than skin deep, as common skin conditions can carry significant psychological impact, influencing quality of life and emotional well-being.

Key Points: 
  • Groundbreaking State of Skin Sensitivity report raises awareness of the causes of skin sensitivity, and its mind-body connection
    SKILLMAN, N.J., Oct. 25, 2022 /PRNewswire/ -- Today, the Aveeno brand launched its first-ever State of Skin Sensitivity Report , which examines the causes of sensitive skin, and explores the connection between body, mind, and skin.
  • The groundbreaking Aveeno report shows that 71% of adults identify as having sensitive skin1,2, an astounding increase of 55%3,4 in just two decades.
  • Research from the State of Skin Sensitivity report validates the relationship between emotions and perceptions of sensitive skin.
  • The brand is committed to igniting and fueling the positive narrative around sensitive skin, while also being dedicated to delivering products that bring nourishing solutions to sensitive skin.

Announcing Vivvi & Bloom™: Simple, Proven and Positive Skin & Hair Care Products Developed for Little Ones

Retrieved on: 
Thursday, July 21, 2022
ISO, Village, Listerine, Ageing, Partnership, Parent, Safety, Johnson, BABY, Shea butter, Security (finance), Tylenol, Wash, Dry, Skin, Sulfate, Water, Feedback, U.S. Securities and Exchange Commission, Aveeno, Research, EWG, Johnson & Johnson, Caregiver, MSRP, OGX, Biophysical environment, Coconut oil, Walmart, Risk, Scalp, Health, Paraben, Sunflower oil, Science, Annual report, Environmental Working Group, Johnson's Baby, Millennials, Trial of the century, Silicone, Hospital, Neutrogena, Private Securities Litigation Reform Act, HEB, Volunteering, Behavior, Animal, Rite Aid, Pharmaceutical industry, Toy, Cosmetics, Tutoring, Birth control, Wegmans, Meijer, Amazon

SKILLMAN, N.J., July 21, 2022 /PRNewswire/ -- Johnson & Johnson Consumer Health† announced today the launch of Vivvi & Bloom™, a new skin & hair care brand for babies and toddlers developed to be intentionally simple through its purposeful ingredients, purposeful mission, and purposeful science. The Vivvi & Bloom™ brand was uniquely co-created and designed to meet the expressed needs of Millennial and Gen-Z parents and caregivers to streamline their baby care routine.

Key Points: 
  • Vivvi & Bloom products are verified by the Environmental Working Group (EWG).
  • The products contain simple and nature-inspired ingredients, including responsibly-sourced shea butter, and clinically proven formulas.
  • Vivvi & Bloom products are clinically proven to be gentle and safe on all skin tones and hair types.
  • Through their partnership with Newborns In Need , Vivvi & Bloom perpetuates positivity in baby care.

REACTINE® and Tree Canada collaborate to improve the lives of Canadians

Retrieved on: 
Thursday, May 19, 2022
Tree Canada, 2010 Johnson & Johnson children's product recall, Sneeze, Private Securities Litigation Reform Act, McNeil Consumer Healthcare, Climate change, Camping, U.S. Securities and Exchange Commission, RL, Listerine, Seedling, Greenhouse effect, Science, Health, Itchy, Tree, Nature, National academy, EST, Tylenol, Aveeno, OGX, Johnson & Johnson, Method, Research, Carbon, Pollen, Partnership, Nasal congestion, Instagram, Air pollution, Nose, Behavior, Neutrogena, Oxygen, Security (finance), Risk, Annual report, Informatics for Consumer Health, Pharmaceutical industry

As part of this collaboration, REACTINE is sponsoring a portion of Tree Canada's National Greening Program, where more than 800,000 trees will be planted across Canada this year.

Key Points: 
  • As part of this collaboration, REACTINE is sponsoring a portion of Tree Canada's National Greening Program, where more than 800,000 trees will be planted across Canada this year.
  • REACTINE will be working with Tree Canada to support the planting of more than 5,800 seedlings across the country as part of Tree Canada's National Greening Program.
  • "We are thrilled to be partnering with REACTINE," says Michael Petryk, director of operations, Tree Canada.
  • REACTINE is owned byToronto, ON-based, McNeil Consumer Healthcare, division of Johnson & Johnson Inc.
    For more information on REACTINE products, please visit Reactine.ca or www.Facebook.com/ReactineCA .